You have 9 free searches left this month | for more free features.

ROS1

Showing 1 - 25 of 991

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

Recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • +4 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jan 8, 2023

Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Tumors Trial in Guangzhou (JYP0322)

Recruiting
  • Protein Kinase Inhibitors
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Nov 9, 2023

NSCLC(NSCLC) Trial in Jinan (WX-0593 Tablets)

Not yet recruiting
  • Non-Small Cell Lung Cancer(NSCLC)
  • WX-0593 Tablets
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Mar 1, 2023

NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Department of Thoracic Surgery and Oncology, The First Affiliate
Mar 17, 2023

Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Providence (TY-2136b)

Not yet recruiting
  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Providence, Rhode Island
    Rhode Island Hospital, Brown University
Mar 2, 2023

Advanced or Metastatic ROS1-Positive NSCLC Trial in Guangzhou (Lorlatinib)

Recruiting
  • Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's hospital
May 31, 2022

Nonsmall Cell Lung Cancer Trial in Goyang-Si (Lorlatinib)

Recruiting
  • Nonsmall Cell Lung Cancer
  • Goyang-Si, Gyeonggi-do, Korea, Republic of
    National Cancer Center
Apr 4, 2022

Advanced Malignant Tumor, ALK Fusion Protein Expression, ALK Gene Amplification Trial in Columbus (Brigatinib, Laboratory

Withdrawn
  • Advanced Malignant Neoplasm
  • +10 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

Withdrawn
  • Non-Small Cell Lung Cancer
  • InVisionFirst-Lung ctDNA assay
  • Los Angeles, California
  • +2 more
Sep 16, 2022

Tolerance of Brigatinib in Management of Rearranged CBNPC ROS1

Completed
  • Lung Cancer ROS Translocated
    • Créteil, France
      CHI Créteil
    Nov 19, 2021

    First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous

    Recruiting
    • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Hunan Cancer Hospital
    Mar 1, 2022

    Locally Advanced or Metastatic Solid Tumors, Locally Advanced or Metastatic NSCLC Trial in Beijing (XZP-5955 tablets)

    Recruiting
    • Locally Advanced or Metastatic Solid Tumors
    • Locally Advanced or Metastatic Non-small Cell Lung Cancer
    • XZP-5955 tablets
    • Beijing, Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    May 17, 2022

    Invasive Lobular Breast Carcinoma, ER+ Breast Cancer, HER2-negative Breast Cancer Trial in Belgium, France (Entrectinib,

    Recruiting
    • Invasive Lobular Breast Carcinoma
    • +2 more
    • Brussels, Belgium
    • +9 more
    May 4, 2022

    Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Crizotinib)

    Active, not recruiting
    • Advanced Lymphoma
    • +5 more
    • Philadelphia, Pennsylvania
      ECOG-ACRIN Cancer Research Group
    Feb 4, 2022

    ROS1 Rearrangement NSCLC, ALK Rearrangement NSCLC Trial in ShangHai (XZP-3621)

    Recruiting
    • ROS1 Rearrangement Non-small Cell Lung Cancer
    • ALK Rearrangement Non-small Cell Lung Cancer
    • ShangHai, Shanghai, China
      Shanghai Chest hospital affiliated to Shanghai jiao tong univers
    Sep 14, 2021

    Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Worldwide (NVL-520)

    Recruiting
    • Locally Advanced Solid Tumor
    • Metastatic Solid Tumor
    • Orange, California
    • +18 more
    Oct 6, 2022

    Safety and Efficacy of Xalkori ROS1

    Recruiting
    • Non-small Cell Lung Cancer
    • Tokyo, Japan
      Pfizer local country office
    Aug 26, 2021

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    PD-1 Antibody Plus Chemotherapy for TKI Failure Driver Gene

    Recruiting
    • Non Small Cell Lung Cancer
      • Changsha, Hunan, China
        Yongchang Zhang
      Mar 9, 2022

      Nsclc, EGFR Activating Mutation, EGF-R Positive NSCLC Trial in Hong Kong (Pembrolizumab, Lenvatinib, Pemetrexed)

      Recruiting
      • Nsclc
      • +5 more
      • Hong Kong, Hong Kong
        Queen Mary Hospital
      Nov 25, 2021

      Advanced Solid Tumor, Metastatic Solid Tumor Trial in Canton (TPX-0005, Metformin Hydrochloride, Digoxin)

      Recruiting
      • Advanced Solid Tumor
      • Metastatic Solid Tumor
      • Canton, Ohio
        Gabrail Cancer Research Center
      Apr 25, 2023

      Hematologic Cancers, Solid Tumors, Metastatic Cancer Trial in Villejuif (Crizotinib)

      Active, not recruiting
      • Hematologic Cancers
      • +2 more
      • Villejuif, Ile De France, France
        Gustave Roussy
      Sep 5, 2022

      Non Small Cell Lung Cancer, Stage IV NSCLC, Recurrent Non Small Cell Lung Cancer Trial in Tampa (biological, drug, other)

      Recruiting
      • Non Small Cell Lung Cancer
      • +2 more
      • Tumor-infiltrating Lymphocytes (TIL)
      • +5 more
      • Tampa, Florida
        Moffitt Cancer Center
      Dec 28, 2022

      Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI

      Recruiting
      • Non-Small Cell Carcinoma of Lung, TNM Stage 4
      • +5 more
        • Aurora, Colorado
          University of Colorado, Cancer Center
        Nov 3, 2021

        NSCLC Trial in Guangzhou (TGRX-326)

        Recruiting
        • Non-small Cell Lung Cancer
        • Guangzhou, Guangdong, China
          Sun Yat-sen University Cancer Center
        Jun 29, 2022